Lineage Cell Therapeutics Inc. (LCTX)
NYSE: LCTXHealthcareBiotechnologyUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
LCTX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $239.66M
- EPS (TTM)
- -$0.19
- Dividend yield
- None
- Ex-dividend date
- Dec 15, 2003
- 52-week range
- 0.88 – 2.09
- Day range
- 0.9212 – 0.965
- Volume / Avg
- 1.48M / 1.15M
- Beta
- —
- Shares outstanding
- 252.91M
- Next earnings
- Nov 5, 2026
52-week range
LCTX stock today
On Oct 7, LCTX ended the session at $0.9476, adding $0.0097 (1.03%), versus the S&P 500's 0.22% decline. Shares are 54.7% below their 52-week high of $2.09, set on Nov 3, 2025 and 7.7% above the 52-week low of $0.88, near the bottom of the past year's range. LCTX is down 43.3% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 45.2%.
Lineage Cell Therapeutics has posted a net loss over the last twelve months (EPS of -$0.19), so its P/E ratio is not meaningful. Lineage Cell Therapeutics's next earnings report is expected on Nov 5, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Lineage Cell Therapeutics
Company profileLineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Brian M. Culley M.A., M.B.A.
- Headquarters
- Carlsbad, CA
- Employees
- 72
- Website
- lineagecell.com
Analyst forecast
ForecastConsensus (7 analysts)
strong_buy
Avg. price target
$5.50+480.41%
- Strong buy 1
- Buy 5
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 5, 2026
- EPS estimate
- $-0.02
Dividends
Dividend history- Annual dividend
- $0.00
- Last payment
- $0.0646
- Ex-dividend date
- Dec 15, 2003
Lineage Cell Therapeutics peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| QTTBQ32 Bio Inc. | 7.99 | -1.48% | $237.86M | vs LCTX |
| SLGLSol-Gel Technologies Ltd. | 71.95 | -4.88% | $235.55M | vs LCTX |
| VOGXVogenx Inc | 16.16 | -1.40% | $240.06M | vs LCTX |
| PYXSPyxis Oncology Inc. | 2.01 | -0.49% | $240.11M | vs LCTX |
| CAMPCAMP4 Therapeutics Corporation | 3.84 | -3.03% | $240.97M | vs LCTX |
| IPSCCentury Therapeutics Inc. | 1.28 | -3.03% | $231.78M | vs LCTX |
| STROSutro Biopharma Inc. | 14.66 | +1.45% | $243.08M | vs LCTX |
| PRQRProQR Therapeutics N.V. | 1.63 | -1.21% | $230.02M | vs LCTX |
Indexes, lists and sector
Lineage Cell Therapeutics stock FAQ
What is Lineage Cell Therapeutics's stock price today?
LCTX last traded at $0.9476 as of Oct 7, 4:00 PM EDT, up 1.03% on the day. Prices are delayed at least 15 minutes.
Does Lineage Cell Therapeutics pay a dividend?
Yes. Lineage Cell Therapeutics pays $0.00 per share annually. The most recent dividend of $0.0646 had an ex-dividend date of Dec 15, 2003.
When is Lineage Cell Therapeutics's next earnings date?
Lineage Cell Therapeutics is expected to report earnings on Thursday, November 5, 2026. Analysts expect EPS of $-0.02.
Who is Lineage Cell Therapeutics's CEO?
Mr. Brian M. Culley M.A., M.B.A. is the chief executive officer of Lineage Cell Therapeutics Inc., which has about 72 employees.
Has LCTX ever split its stock?
Yes. The most recent LCTX stock split was a 3-for-1 split on Oct 31, 1997.
What is the LCTX 52-week high?
The 52-week high for LCTX is $2.09 and the 52-week low is $0.88. The stock is currently 54.7% below its high.